Progestogen-only contraceptives and the risk of stroke: a meta-analysis.

Archive ouverte

Chakhtoura, Zeina | Canonico, Marianne | Gompel, Anne | Thalabard, Jean-Christophe | Scarabin, Pierre-Yves | Plu-Bureau, Geneviève

Edité par CCSD ; American Heart Association -

International audience. The association between combined oral contraceptives (OC) use and increased risk of stroke has been reported. While progestogen-only contraceptives (POC) are commonly used worldwide, their impact on cardiovascular disease remains unclear. A meta-analysis based on EMBASE and MEDLINE referenced literature corresponding to OCs marketed since 1960 was carried out. Eligible articles assessing the risk of stroke in relation to OC or POC were reviewed, and relevant studies were extracted. All types of POC and routes of administration were taken into account in the meta-analysis. Six case-control studies were identified. The combined odd ratio (OR) showed no increase in the risk of stroke among POC users (OR=0.96; 95% confidence interval: 0.70 to 1.31). This result was similar according to the route of administration (either implant or injectable or oral POC). Data from observational studies show that POC use is not associated with an increased risk of stroke. However, these results are based on limited data. Further investigations are needed in women with risk factors of stroke.

Suggestions

Du même auteur

Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis.

Archive ouverte | Chakhtoura, Zeina | CCSD

International audience. The association between combined oral contraceptives (OC) and the risk of myocardial infarction (MI) has been intensively studied, and conclusions are controversial. While progestogen-only co...

Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative Hormone Therapy clinical trials.

Archive ouverte | Canonico, Marianne | CCSD

International audience. This study aims to investigate venous thromboembolism (VTE) risk in relation to age at menopause, age at menarche, parity, bilateral oophorectomy, and time since menopause, as well as any int...

Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.

Archive ouverte | Canonico, Marianne | CCSD

International audience. BACKGROUND: Oral estrogen therapy increases the risk of venous thromboembolism (VTE) in postmenopausal women. Transdermal estrogen may be safer. However, currently available data have limited...

Chargement des enrichissements...